Peptides Similar to Nomlabofusp
Compare Nomlabofusp with related peptides and alternatives
📌TL;DR
- •2 similar peptides identified
- •Cerebrolysin: Both are protein-based neuroprotective therapies administered by injection. Cerebrolysin contains neurotrophic peptide fragments; nomlabofusp delivers frataxin via CPP technology. Both target neurodegenerative processes.
- •Davunetide: Both are neuroprotective agents that use peptide-based approaches to target neurodegenerative diseases. Both were developed for rare neurological conditions.
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Nomlabofusp (current) | - | - |
| Cerebrolysin | Both are protein-based neuroprotective therapies administered by injection. Cerebrolysin contains neurotrophic peptide fragments; nomlabofusp delivers frataxin via CPP technology. Both target neurodegenerative processes. | Cerebrolysin is a mixture of porcine-derived peptides targeting general neurodegeneration (stroke, Alzheimer's). Nomlabofusp is a defined recombinant protein targeting a specific genetic deficiency (frataxin in FA). Different indications, mechanisms, and regulatory pathways. |
| Davunetide | Both are neuroprotective agents that use peptide-based approaches to target neurodegenerative diseases. Both were developed for rare neurological conditions. | Davunetide (NAP/AL-108) is an 8-amino acid neuroprotective peptide targeting microtubule stability, studied for progressive supranuclear palsy and Alzheimer's. Nomlabofusp is a fusion protein delivering a specific mitochondrial protein. Different targets, mechanisms, and diseases. |
CerebrolysinBoth are protein-based neuroprotective therapies administered by injection. Cerebrolysin contains neurotrophic peptide fragments; nomlabofusp delivers frataxin via CPP technology. Both target neurodegenerative processes.
Differences
Cerebrolysin is a mixture of porcine-derived peptides targeting general neurodegeneration (stroke, Alzheimer's). Nomlabofusp is a defined recombinant protein targeting a specific genetic deficiency (frataxin in FA). Different indications, mechanisms, and regulatory pathways.
Advantages
Targeted disease-modifying mechanism. Defined molecular composition. Addresses root cause of Friedreich ataxia. Multiple regulatory designations (Fast Track, Orphan, PRIME).
Disadvantages
Investigational (not yet approved). Limited to Friedreich ataxia. Requires daily injection. Risk of anaphylaxis. Narrow patient population.
DavunetideBoth are neuroprotective agents that use peptide-based approaches to target neurodegenerative diseases. Both were developed for rare neurological conditions.
Differences
Davunetide (NAP/AL-108) is an 8-amino acid neuroprotective peptide targeting microtubule stability, studied for progressive supranuclear palsy and Alzheimer's. Nomlabofusp is a fusion protein delivering a specific mitochondrial protein. Different targets, mechanisms, and diseases.
Advantages
Disease-modifying protein replacement rather than symptomatic treatment. Strong surrogate endpoint data (frataxin restoration). Clear regulatory pathway with FDA engagement.
Disadvantages
Limited to a single rare disease indication. Requires daily injection versus intranasal administration. Anaphylaxis risk.
Therapeutic Landscape for Friedreich Ataxia#
Nomlabofusp occupies a unique position as the only frataxin protein replacement therapy in clinical development. The FA treatment landscape includes one approved therapy and several investigational approaches targeting different aspects of FA pathophysiology.
Omaveloxolone (Skyclarys) -- FDA Approved#
Omaveloxolone is the first and currently only FDA-approved therapy for Friedreich ataxia (approved February 2023). It is a small molecule NRF2 activator that upregulates antioxidant defense pathways.
Mechanism comparison: Omaveloxolone addresses downstream consequences of frataxin deficiency (oxidative stress) by activating NRF2-mediated antioxidant responses. Nomlabofusp addresses the root cause by directly replacing the missing frataxin protein.
Clinical data: In the MOXIe trial, omaveloxolone showed a 2.40-point mFARS improvement relative to placebo at 48 weeks. Nomlabofusp open-label data show a median 2.25-point mFARS improvement at 1 year, but in an uncontrolled comparison to natural history.
| Parameter | Nomlabofusp | Omaveloxolone |
|---|---|---|
| Class | Protein replacement | NRF2 activator |
| Route | SC injection (daily) | Oral (daily) |
| Frataxin restoration | Yes (direct) | No |
| Mechanism level | Root cause | Downstream |
| Clinical endpoint | mFARS (trends) | mFARS (significant) |
| Regulatory | Phase 2/BLA planned | FDA-approved |
| Key risk | Anaphylaxis | Hepatotoxicity |
AAV Gene Therapy (LX2006, AAVrh.10hFXN)#
Several gene therapy programs aim to provide lasting frataxin expression through viral vector-mediated FXN gene delivery.
Mechanism comparison: Gene therapy provides a potentially one-time or limited treatment by inserting functional FXN gene copies, enabling endogenous frataxin production. Nomlabofusp provides frataxin protein directly but requires daily dosing.
Current status: LX2006 (Lexeo Therapeutics) is in Phase 1/2 for FA cardiomyopathy. AAVrh.10hFXN was the first gene therapy studied in humans for FA (2022). Both are earlier in development than nomlabofusp.
| Parameter | Nomlabofusp | AAV Gene Therapy |
|---|---|---|
| Approach | Protein replacement | Gene delivery |
| Dosing | Daily SC injection | Single/limited IV infusion |
| Duration of effect | Requires continuous dosing | Potentially durable |
| Tissue targeting | Broad (CPP-mediated) | Vector tropism-dependent |
| Risk profile | Anaphylaxis, ISRs | Vector immunogenicity, hepatotoxicity |
| Stage | Phase 2/BLA planned | Phase 1/2 |
| Indication breadth | Neurological + systemic FA | Cardiac FA (LX2006) |
Cerebrolysin#
Cerebrolysin is a neuropeptide preparation containing low-molecular-weight neurotrophic factors derived from porcine brain tissue, used for neurological conditions including stroke and neurodegenerative diseases.
Relevance: Both are injectable protein/peptide-based neuroprotective agents, but they target entirely different conditions and pathways. Cerebrolysin provides general neurotrophic support while nomlabofusp delivers a specific missing protein.
Davunetide (NAP/AL-108)#
Davunetide is a synthetic 8-amino acid neuroprotective peptide derived from activity-dependent neuroprotective protein (ADNP) that promotes microtubule stability. It was studied for progressive supranuclear palsy and Alzheimer's disease.
Relevance: Both represent peptide-based approaches to neurodegeneration, though targeting different diseases and mechanisms. Davunetide's Phase 2/3 trial in PSP did not meet its primary endpoint, highlighting the challenge of developing neuroprotective therapies.
Other Investigational FA Therapies#
| Agent | Mechanism | Status |
|---|---|---|
| Vatiquinone | NQO1 activator | Phase 3 (pediatric) |
| Elamipretide | Cardiolipin stabilizer | Phase 2 (cardiac FA) |
| Nicotinamide riboside | NAD+ precursor | Phase 2 |
| Dimethyl fumarate | NRF2 activator | Phase 2 |
Summary Comparison#
| Feature | Nomlabofusp | Omaveloxolone | Gene Therapy | Vatiquinone |
|---|---|---|---|---|
| Mechanism | FXN replacement | NRF2 activation | Gene delivery | NQO1 activation |
| Route | SC daily | Oral daily | IV single | Oral daily |
| FXN restoration | Yes | No | Potentially | No |
| Status | Phase 2/BLA | Approved | Phase 1/2 | Phase 3 |
| Disease modification | Root cause | Downstream | Root cause | Downstream |
Related Reading#
Frequently Asked Questions About Nomlabofusp
What are the main alternatives to nomlabofusp for Friedreich ataxia?
The only FDA-approved therapy for FA is omaveloxolone (Skyclarys), which activates NRF2 antioxidant pathways but does not restore frataxin. Other investigational approaches include AAV-based gene therapy (LX2006, targeting cardiac FA), vatiquinone (an NQO1 activator), and elamipretide (a mitochondrial peptide). Nomlabofusp is unique as the only frataxin protein replacement therapy.
How does nomlabofusp compare to omaveloxolone?
Omaveloxolone (Skyclarys) is an oral NRF2 activator that provides modest clinical benefit (2.4-point mFARS improvement vs placebo at 48 weeks) without restoring frataxin. Nomlabofusp directly replaces the missing frataxin protein and has shown carrier-equivalent frataxin restoration. However, omaveloxolone is approved while nomlabofusp is investigational, and omaveloxolone is oral vs daily injection.
How does nomlabofusp compare to gene therapy for FA?
Gene therapy aims to provide lasting frataxin production from a single or limited number of treatments using viral vectors (AAV). Nomlabofusp requires daily dosing but is further advanced in clinical development and avoids risks of viral vector immunogenicity and insertional mutagenesis. AAV gene therapy for FA is currently in Phase 1/2 for cardiac FA only.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer